# Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients

> **NCT00999882** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 26 (actual)

## Conditions studied

- Cancer
- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** AZD8055

## Key facts

- **NCT ID:** NCT00999882
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2012-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00999882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00999882, "Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of Tor Kinase Inhibitor in Liver Cancer Patients". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00999882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*